An AI Match Is Not a Licensing Deal

Start with two business cases. The first is operational: can staff identify and assess relevant opportunities with less effort? The second is commercial: do those opportunities produce useful collaborations, licensing income or products that reach users? One may improve without the other.

WIPO’s guidance describes technology transfer as a process that includes evaluation, protection, a business case, marketing, licensing and product development. It also points to conditions outside the research institution: firms able to invest, buyers willing to purchase and the capacity to apply new knowledge. Faster search does not supply these conditions. ²

For a corporate buyer, the value may be earlier access to a useful solution rather than ownership of another patent. For a university, public benefit or wider use may matter alongside income. Agree the intended return before selecting the software. Otherwise, a tool built to maximise discovery activity can be judged against an outcome it was never designed to deliver.

Choose a defined portfolio and a period for the trial. Preserve the opportunities the system rejects as well as those it recommends. Record how many assets were eligible, how many matches passed expert review, how many prospective partners confirmed a relevant need and how many agreed to a next step.

Use a comparable group assessed through the current process. The comparison should have similar technical maturity, rights clarity and commercial support. An AI-assisted team working on the best-documented assets should not be compared with an understaffed team clearing an old backlog.

Keep the costs visible: data preparation, subscriptions, staff review, technical diligence and follow-up. A low cost per generated proposal can conceal a high cost per qualified opportunity. Define qualification before the trial begins, with evidence of a buyer problem, an appropriate contact and a feasible route to evaluation.

Licensing can take longer than a short software trial. Use interim measures without pretending they are revenue: a confirmed evaluation, a funded feasibility study or an agreed technical milestone. Continue tracking the original group after the initial trial so that unsuccessful opportunities do not disappear from the denominator.

A plausible match is a reason to investigate. It is not proof that the technology is ready, that the proposed partner wants it or that the institution can offer every right needed. Separate the commercialisation team’s assessment from the model’s explanation, and keep the underlying evidence available for challenge.

WIPO describes licensing as a contractual arrangement with agreed conditions, including the scope of the permitted use. Its guidance distinguishes licensing from an assignment of ownership and notes the role of associated knowledge in technology transfer. These are matters to resolve with the parties, not conclusions a matching score can settle. ³

New research also points towards agents that can discover and use services across governed data environments. A September preprint demonstrates an architectural approach to connecting agents with such environments. That is an enabling direction, not evidence of completed deals or legal compliance. ⁴

Test what information the tool may access and disclose before giving it confidential research records. Require human approval for external proposals and changes to commercial terms. Stop the trial if recommendations cannot be traced to usable evidence or if reviewers spend more time correcting the output than progressing qualified opportunities.

The NUSX announcement concerns one institution’s platform. It does not establish results for other universities, companies or regions. A well-organised research portfolio and an established industry network may be part of the advantage; a buyer should investigate what would have to be recreated locally.

For a cross-border opportunity, the review should cover the intended market, the rights available there, the language of supporting records, permitted data sharing and the partner’s ability to develop the technology. WIPO’s guidance makes the market and institutional conditions material to transfer. ² A global list of names is not evidence that those conditions are present.

The evidence reviewed does not provide comparative conversion rates for North America, Europe and the UK, Asia-Pacific, Africa and the Middle East, or Latin America. Do not rank these regions from a Singapore launch. In any market with thin buyer information or limited development finance, check whether discovery is actually the binding constraint before buying a discovery tool.

Give the commercialisation or innovation lead ownership of the trial, with finance agreeing the measures and the relevant specialists reviewing technical and rights questions. Set a spending limit, a review date and a rule for expanding or stopping before the results arrive.

Build the evidence record and qualification process. Test the matching capability on a bounded portfolio. Buy wider access only if it improves a meaningful stage of the work at an acceptable total cost. Watch whether qualified opportunities progress; ignore impressive proposal volumes without a buyer response.

The next investment discussion should show both time saved and what happened afterwards. AI-assisted discovery may open a useful route from research to market. The case for scale rests on the quality and progress of the opportunities, not on how quickly the system can produce another list.